Reference range(s)
The reference ranges listed below are valid on this date of December 5, 2024.
Component | Age | Male Norm | Male Critical Low | Male Critical High | Female Norm | Female Critical High | Female Critical Low | Units | Add'l info |
---|---|---|---|---|---|---|---|---|---|
2C19GENO Specimen | ALL | See report. | |||||||
CYP2C19 Genotype | ALL | See report. | |||||||
CYP2C19 Phenotype | ALL | See report. | |||||||
2C19GENO Interpretation | ALL | Recommendation... Note1 | |||||||
EER CYP2C19 | ALL | See report. |
Note1:
Recommendation: Guidelines for genotype-based dosing are published by the Clinical Pharmacogenetics Implementation
Consortium (CPIC) and can be found at: https://cpicpgx.org/ and https://www.pharmgkb.org/
BACKGROUND INFORMATION
Characteristics: The cytochrome P450 (CYP) Isozyme 2C19 is involved in the metabolism of many drugs. Variants in the gene that code for CYP2C19 will influence pharmacokinetics of CYP2C19 substrates, and may predict or explain non- standard dose requirements, therapeutic failure or adverse reactions
Inheritance: Autosomal codominant
Cause: CYP2C19 gene variants affect enzyme function
Variants Tested: (Variants are numbered according to NM_000769 transcript)
*1: Indicative of no detected targeted variants and an assumption of functional allele. No variants detected is predictive of the *1 functional allele
CYP2C19*2: rs4244285, c.681G>A; rs12769205, c.332-23A>G
CYP2C19*3: rs4986893, c.636G>A
CYP2C19*4A: rs28399504, c.1A>G
CYP2C19*4B: rs28399504, c.1A>G; rs12248560, c.-806C>T
CYP2C19*5: rs56337013, c.1297C>T
CYP2C19*6: rs72552267, c.395G>A
CYP2C19*7: rs72558186, c.819+2T>A
CYP2C19*8: rs41291556, c.358T>C
CYP2C19*9: rs17884712, c. 431G>A
CYP2C19*17: rs12248560, c.-806C>T
CYP2C19*35: rs12769205, c.332-23A>G
Clinical Sensitivity: Drug-dependent
Methodology: Polymerase chain reaction (PCR) and fluorescence monitoring
Analytical Sensitivity and Specificity: Greater than 99 percent
Limitations: Only the targeted CYP2C19 variants will be detected by this panel, and assumptions about phase and content are made to assign alleles. Publicly available sources such as the www.pharmvar.org or www.pharmgkb.org provide guidance on phenotype predictions and allele frequencies. Diagnostic errors can occur due to rare sequence variations. Risk of therapeutic failure or adverse reactions with CYP2C19 substrates may be affected by genetic and non-genetic factors that are not detected by this test. This result does not replace the need for therapeutic drug or clinical monitoring
Please note the information contained in this report does not contain medication recommendations, and should not be interpreted as recommending any specific medications. Any dosage adjustments or other changes to medications should be evaluated in consultation with a medical provider
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug
Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes
See report..